In 1968 was created Hambrecht & Quist Capital Management, which is appeared as Corporate Investor. The main department of described Corporate Investor is located in the Boston. The venture was found in North America in United States.
The current fund was established by William R. Timken.
Among the most successful fund investment fields, there are Biotechnology, Medical Device. Among the various public portfolio startups of the fund, we may underline Shopzilla, Cygent, Raven Biotechnologies The fund has exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
The real fund results show that this Corporate Investor is 12 percentage points less often commits exit comparing to other companies. The usual things for fund are deals in the range of 10 - 50 millions dollars. This Hambrecht & Quist Capital Management works on 31 percentage points more the average amount of lead investments comparing to the other organizations. The fund is generally included in less than 2 deals every year. The increased amount of exits for fund were in 2003. When the investment is from Hambrecht & Quist Capital Management the average startup value is 50-100 millions dollars.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Hambrecht & Quist Capital Management, startups are often financed by Forward Ventures, Enterprise Partners, William Blair. The meaningful sponsors for the fund in investment in the same round are U.S. Venture Partners (USVP), SoftBank, OrbiMed. In the next rounds fund is usually obtained by Granite Ventures, Tekla Capital Management, TCV.
Related Funds
Funds with similar focus
Fund Name | Location |
Ankang Venture Investment | - |
Barclays Investment Bank | Atlanta, Georgia, United States |
CK Venture Capital | Bayern, Germany, Unterschleißheim |
CLN Group | Caselette, Italy, Piemont |
Communication Ventures | - |
Dongguan Zhongke Zhongguang Chuangye Touzi Co., Ltd. | - |
Inga Britt & Arne Lundberg Research Foundation | Mölndal, Sweden, Vastra Gotaland |
Japan Tobacco | Japan, Tokyo |
Junda Investment | China, Hainan, Hainan Province |
K2 Investment | China, Hong Kong, Hong Kong Island |
Lord Baltimore Investment Partners | - |
Lurie Investment Fund | Chicago, Illinois, United States |
NDRC VentureLab | County Dublin, Dublin, Ireland |
Northeast Ohio Student Venture Fund | - |
SB Players | Japan, Tokyo |
Vireo Ventures | Berlin, Berlin, Germany |
Windquest Group | Grand Rapids, Michigan, United States |
Works Applications | Chiba Prefecture, Japan, Tateyama |
Xiaoyingtao Keji | - |
Zhejiang Furun | China, Zhejiang, Zhuji |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Veniti | $9M | 04 Jun 2013 | Fremont, California, United States | ||
Veniti | $13M | 07 Mar 2011 | Fremont, California, United States | ||
Tibion Bionic Technologies | $10M | 01 Mar 2011 | California, United States | ||
Euthymics Bioscience | $24M | 22 Jul 2010 | Cambridge, Massachusetts, United States | ||
Eleme Medical | $18M | 16 Jul 2008 | Merrimack, New Hampshire, United States | ||
CardioKinetix | $14M | 15 Jul 2008 | California, United States | ||
$30M | 30 Aug 2007 | Sunnyvale, California, United States | |||
Xanthus Pharmaceuticals | $25M | 01 Dec 2006 | Cambridge, Massachusetts, United States | ||
Idun Pharmaceuticals | $27M | 15 Jun 2004 | San Diego, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Veniti | $9M | 04 Jun 2013 | Fremont, California, United States | ||
Veniti | $13M | 07 Mar 2011 | Fremont, California, United States | ||
Tibion Bionic Technologies | $10M | 01 Mar 2011 | California, United States | ||
Euthymics Bioscience | $24M | 22 Jul 2010 | Cambridge, Massachusetts, United States | ||
Eleme Medical | $18M | 16 Jul 2008 | Merrimack, New Hampshire, United States | ||
CardioKinetix | $14M | 15 Jul 2008 | California, United States | ||
$30M | 30 Aug 2007 | Sunnyvale, California, United States | |||
Xanthus Pharmaceuticals | $25M | 01 Dec 2006 | Cambridge, Massachusetts, United States | ||
Idun Pharmaceuticals | $27M | 15 Jun 2004 | San Diego, California, United States |